Sign In
Buy MGNX
$4.69
+0.110 (+2.40%)
At Close: Jun 23, 2026
Head to Head Review: MacroGenics (NASDAQ:MGNX) & Sharps Technology (NASDAQ:STSS)
01:28am, Monday, 08'th Dec 2025
MacroGenics (NASDAQ: MGNX - Get Free Report) and Sharps Technology (NASDAQ: STSS - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two compa
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference
04:05pm, Tuesday, 25'th Nov 2025
ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer
MacroGenics (MGNX) Q3 Earnings and Revenues Surpass Estimates
06:15pm, Wednesday, 12'th Nov 2025
MacroGenics (MGNX) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of a loss of $0.48 per share. This compares to earnings of $0.9 per share a year ago.
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress
04:01pm, Wednesday, 12'th Nov 2025
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer
MacroGenics (MGNX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
10:56am, Monday, 10'th Nov 2025
After losing some value lately, a hammer chart pattern has been formed for MacroGenics (MGNX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate rev
MacroGenics to Participate in the Stifel 2025 Healthcare Conference
04:30pm, Thursday, 06'th Nov 2025
ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,
MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference
04:30pm, Tuesday, 02'nd Sep 2025
ROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cance
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates
06:15pm, Thursday, 14'th Aug 2025
MacroGenics (MGNX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $0.89 per share a year ago.
MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities
04:01pm, Thursday, 14'th Aug 2025
ROCKVILLE, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the trea
MacroGenics Appoints Eric Risser as President and Chief Executive Officer
04:01pm, Wednesday, 13'th Aug 2025
ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of ca
MacroGenics: Working On That Road To Recovery
06:32pm, Wednesday, 11'th Jun 2025
I maintain a tentative 'Buy' on MacroGenics, Inc., but acknowledge increased risk after the vobra duo failure and ongoing cash flow challenges. Lorigerlimab is now the lead pipeline candidate, with ke
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
07:00am, Tuesday, 10'th Jun 2025
MacroGenics received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard) MacroGenics' cash runway extended through first half of 2027 ROCKVILLE, MD, June 10, 2025 (GLOBE NEWSWIRE
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
04:30pm, Tuesday, 03'rd Jun 2025
ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibod
4 Medical Product Stocks to Watch From a Challenging Industry
12:41pm, Wednesday, 21'st May 2025
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fu
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates
06:20pm, Tuesday, 13'th May 2025
MacroGenics (MGNX) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.84 per share a year ago.
